Otonomy raises $10 million for disorders of the inner and middle ear
This article was originally published in Scrip
Executive Summary
Otonomy, which is developing therapies for disorders of the inner and middle ear, has raised a $10 million series A financing with Avalon Ventures. The proceeds will be used to fund the ongoing clinical trial of the US firm's lead product OTO-104 in Ménière's disease, toinitiate IND-enabling studies for its next product candidate OTO-203, and for early-stage development of a third programme, said the US firm.